Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis
EVOLVE Trial Investigators × Chertow, Glenn M Block, Geoffrey A Correa-Rotter, Ricardo Drüeke, Tilman B Floege, Jürgen Goodman, William G Herzog, Charles A Kubo, Yumi London, Gerard M Mahaffey, Kenneth W Mix, T Christian H Moe, Sharon M Trotman, Marie-Louise Wheeler, David C Parfrey, Patrick S Evenepoel, Pieter #
New England Journal of Medicine vol:367 issue:26 pages:2482-94
Disorders of mineral metabolism, including secondary hyperparathyroidism, are thought to contribute to extraskeletal (including vascular) calcification among patients with chronic kidney disease. It has been hypothesized that treatment with the calcimimetic agent cinacalcet might reduce the risk of death or nonfatal cardiovascular events in such patients.